Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Teneoseven Inc. operates within the Biotechnology & Pharmaceuticals technology area, where it currently faces 1 pending office action. This level of activity suggests a targeted approach to its intellectual property filings. The prosecution is confined to 1 distinct examiner and 1 distinct art unit, which implies that the technical subject matter is specialized and resides within a specific regulatory framework at the patent office.
The busiest examiner assigned to the portfolio is MERTZ, PREMA MARIA, who is currently processing 1 busiest examiner pending office action. Since there is only 1 pending office action in total, this examiner is responsible for the company's entire active prosecution queue. The presence of 1 distinct art unit indicates that the company has not yet diversified its filings across different technological classifications. Practitioners should note that the singular nature of the 1 distinct examiner means the outcome of the current prosecution cycle rests on the evaluation of 1 official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MERTZ, PREMA MARIA | 1 | 71.8% | +34.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18253197 | HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA | MERTZ, PREMA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18253197 | HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA | MERTZ, PREMA MARIA | 1674 | §112 | Non-Final OA | — | Pending | May 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTeneoseven Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Prema Maria Mertz has the most, with 1 of Teneoseven Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
